JUN 0 5 2002

PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-1031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
OFFICE Authority of Information unless it contains a valid OMB

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of Sheet

Substitute for form 1449A/PTO

Со	mplet if Known			
Application Number	10/009,876		7=1	EIVED
Filing Date	December 11, 2001			サビハトロ
First Named Inventor	R.G.F. Visser		_	1 ~~
Art Unit	TBA		SE	P 1 1 2002
Examiner Name	TBA]
Attorney Docket Number	92750/65	75 <i>(</i>	ים כם	NTER 1600/2900
		16		111EN 1000/2900

U.S. PATENT DOCUMENTS						
Examiner Initials		Document Number Number - Kind Code ² (if known	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
RK	1	us- 6,107,060	08-22-2000	Keeling et al.		
MX	2		05-12-1998	Stalker et al.		
NY	3	us- 5,349,123	09-20-1994	Shewmaker et al.		
701		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
	i	US-				
		US-				
		US-				
		US-				
		US-				
		us-				
		US-				
		us-		***************************************		

	FOREIGN PATENT DOCUMENTS					
	Cite No.1	Foreign Patent Document Country Code 3 "Number 4 - Kind Code 5 (# (mown)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ^B
RK	4	CA 2,061,443	08-19-1993	Visser et al.		
1	5	WO 99/15636	04-01-1999	Novo Nordisk A/S		
	6	WO 98/16190	04-23-1998	Novo Nordisk A/S		
	7	WO 98/14601	04-09-1998	Exseed Genetics LLC		
	8	WO 92/14827	09-03-1992	Institut Fur Genbiologische		
	9	WO 92/11376	07-09-1992	Amylogene HB		
KF	10	WO 91/19808	12-26-1991	Calgene, Inc.		

Examiner Signature	Romall Kally	Date Considered	15	05

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.ngv or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as Indicated on the document under WIPO Standard ST. 16 if possible. 8 Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of

Compl t if Known			
Application Number	10/009,876		
Filing Date	December 11, 2001		
First Named Inventor	R.G.F. Visser		
Group Art Unit	TBA	SEI	
Examiner Name	TBA		
Attorney Docket Number	92750/65		

1 1 2002

ENTER 1600/2900

-		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the	1
RK	11	CHEN et al., Improved Adsorption to Starch of a Beta-Galactosidase Fusion Protein Containing the Starch-Binding Domain from Aspergillus Glucoamylase. Biotechnology Progress, 7:225-29, 1991	
[12 DALMIA et al., Domain E of Bacillus macerans Cyclodextrin Glucanotransferase		DALMIA et al., Domain E of Bacillus macerans Cyclodextrin Glucanotransferase: An Independent Starch-Binding Domain. Biotechnology and Bioengeneering, 47:575-84,1995	
1	13	KUSNADI et al., Functional Starch-Binding Domain of Aspergillus Glucoamylase I in Escherichia Coli. Gene, 127(2):193-97, 1993	
	14	LAWSON et al., Nucleotide Sequence and X-ray Structure of Cyclodextrin Glycosyltransferase from Bacillus circulans Strain 251 in a Maltose-dependent Crystal Form. J. Mol. Biol., 236:590-600, 1994	
	15	OHDAN et al., Introduction of Raw Starch-Binding Domains into Bacillus subtilis Alpha-Amylase by Fusion with the Starch-Binding Domain of Bacillus Cyclomaltodextrin Glucanotransferase. Appl. Environ Microbiol., 66(7):3058-64, 2000	
	16	ONG et al., The Cellulose-Binding Domains of Cellulases: Tools for Biotechnology. Trends in Biotechnology, 7:239-43, 1989	
	17	PENNINGA et al., The Raw Starch Binding Domain of Cyclodextrin Glycosyltransferase from Bacillus circulans Strain 251. J. Biol. Chem, 271(51):32777-32784, 1996	
	18	SORIMACHI et al., Solution Structure of the Granular Starch Binding Domain of Glucoamylase from Aspergillus niger by Nuclear Magnetic Resonance Spectroscopy. J. Mol. Biol., 259(5):970-87, 1996	
	19	SORIMACHI et al., Solution Structure of the Granular Starch Binding Domain of Aspergillus niger Glucoamylase Bound to Beta-Cyclodextrin. Structure, 5(5):647-61, 1997	
RK	20	SVENSSON et al., Sequence homology between putative raw-starch binding domains from different starch-degrading enzymes. Biochem. J., 264:309-11, 1989	

Examiner Signature PWW 00 (4 allu	Date 5/5/05
	T OOTISIOCICAL

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.